These data are significant because they show for the first time that LIMK1 targeted to the nucleus evinces similar signaling pathway activation and tumor-promoting properties as LIMK1 targeted either to the cytoplasm or to both subcellular compartments. Here, LIMK1 is linked to neoplasm.